The guidance provides industry with information on the design and implementation of natural history studies to support the development of treatments for rare diseases.
FDA published guidance on March 25, 2019 detailing the agency’s thoughts on the design and implementation of natural history studies for the development of drugs and biologics for the treatment of rare diseases. The guidance specifically discusses the types of natural history studies, data elements and research plans, and a practical framework for the conduct of a natural history study. Considerations for aligning the study design with study objectives and for enhancing the interpretability of study results are also discussed, as well as patient confidentiality and data protection.
The agency defines a natural history of a disease as the “course a disease takes in the absence of intervention in individuals with the disease, from the disease’s onset until either the disease’s resolution or the individual’s death.” A natural history study is a preplanned observational study that tracks the course of the disease to identify demographic, genetic, environmental, and other variables of the disease that may be used in the development of treatments. Data for these studies may come from diseases registries.
FDA states in the document that while this guidance is focused on rare diseases, the recommendations may also apply to development of other drug products.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.